Introduction of Typhoid Conjugate Vaccines in Africa and Asia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30767005.
- Also identified by DOI 10.1093/cid/ciy878 and PMC identifier 6376078.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Typhoid fever continues to be a major public health concern, particularly in many low- and middle-income countries. The current threats of increasing antimicrobial resistance, urbanization, and climate change elevate the urgency for better prevention and control efforts for typhoid fever. In 2017, the results of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization prequalification of a TCV, and global policy and financing decisions have set the stage for the introduction of TCVs into routine immunization programs in endemic countries. Country-level decision-making and program planning are critical for local uptake and sustainability.
Medical subject headings
- Typhoid Fever
- Typhoid-Paratyphoid Vaccines